Because individuals with pathogenic TSC1/2 variants have an increased baseline risk for LAM, it is advised that estrogen-containing products be limited or avoided in these patients (Yano, 2002; Oberstein et al., 2003). Here, TSC1 is linked to lymphangioleiomyomatosis.